Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 9 and 50 years old at the time of joining the trial
- People who have been living in the selected community for at least the past 3 months (exceptions may apply for pastoralists, refugees, and commercial sex workers)
- People who are able to understand what the study involves and what will be asked of them
- People aged 18 or older, or those legally recognised as an emancipated minor, who are willing and able to give their own consent to take part, including agreeing to sample collection
- People under 18 (who are not legally recognised as an emancipated minor) whose parent or guardian is willing and able to give consent on their behalf
- People under 18 (who are not legally recognised as an emancipated minor) who are themselves willing and able to agree to take part (known as giving "assent")
Who may not be able to join:
- People who do not wish to give consent to take part in any part of the study
- People who have a medical condition or other circumstance — not related to HPV infection or HPV-related diseases — that the study doctor believes would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alexandra Hill, Associate Research Scientist
Phone: +8228811149
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To estimate the prevalence (single time point detection) of HPV 16 and/or 18 infection among a representative sample of girls and women aged 9-50y in a range of settings.; To estimate the incidence of ≥6-month persistent HPV 16 and/or 18 infection (defined as two sequential type-specific positives with an interval of 6 months) in selected populations over 2 years.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.